Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Rivus Pharmaceuticals Announces New Data from Phase 2 M-ACCEL Trial of HU6 in MASH in Late-Breaker Oral Presentation at AASLD The Liver Meeting® 2025
-
Dycom Industries, Inc. to Host Fiscal 2026 Third Quarter Results Conference Call
-
Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025
-
Assembly Biosciences Presents Positive Phase 1b Data for Next-Generation Capsid Assembly Modulator ABI-4334 at AASLD The Liver Meeting®
-
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
-
ESET to aid MSPs by integrating with ConnectWise Asio
-
Dr. Adrian Bot joins Immuthera to support the company with his unique experience in commercialization of groundbreaking cell therapies
-
Press Release: ACAAI: Sanofi and Regeneron’s Dupixent pivotal study met all primary and secondary endpoints, reducing signs and symptoms of allergic fungal rhinosinusitis; sBLA accepted for FDA pri
-
Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting
-
illumin Reports Third Quarter 2025 Financial Results
-
Form 8.3 - Unite Group plc.
-
Form 8.3 - Idox
-
Form 8.3 - Empiric Student Property Plc
-
Form 8.3 - Bluefield Solar Income Fund Ltd.
-
Jackbit Sets New Benchmark for No ID Crypto Casinos
-
AIS 5G Supports The 74th Miss Universe 2025 — Welcomes Global Contestants with Special SIM Packages
-
Barrick Completes Sale of Alturas Project
-
Tree Island Renews Normal Course Issuer Bid
-
Copyseeker Pioneers Visual Search Integration in AI with Model Context Protocol Launch
-
TERRA CLEAN PROVIDES CORPORATE UPDATE
-
Almadex Announces Plans to Drill New Hope Porphyry Project, Arizona and Provides Paradise Drill Program Update
-
Holley Reports Third Quarter 2025 Results
-
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Relmada Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 13, 2025
-
Spectral Medical Announces Third Quarter 2025 Financial Results and Provides Corporate Update
-
Rhythm Pharmaceuticals Announces FDA Extension of Review Period for IMCIVREE® (setmelanotide) for Patients with Acquired Hypothalamic Obesity
-
Barinthus Bio Reports Third Quarter 2025 Financial Results and Updates on Corporate Developments
-
Abeona Therapeutics® Announces Date of Third Quarter Financial Results and Upcoming Investor Conference Participation
-
Context Therapeutics Highlights CT-95 and CT-202 Programs at 2025 SITC Annual Meeting
-
BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ at SITC 2025
-
Nexxen to Announce Third Quarter 2025 Financial Results on November 13, 2025
-
Foremost Hat Launches 2025 Sustainable Beanie Collection for Brands and Retailers
-
Notification of managers’ transactions
-
Evergold Announces Closing of $350,000 Convertible Debenture Private Placement with CJ “Charlie” Greig; Drilling at DEM is Underway
-
Onex Reports Third Quarter 2025 Results
-
Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
MADD Canada Unveils Roadside Memorial Sign in Trenton in Honour of Rebecca Beatty Killed in Impaired Driving Crash
-
Boralex announces its third quarter results and commissioning of large-scale projects in Canada
-
Lagoon Furniture at BDNY 2025 | Stylish & Durable Hospitality Design
-
Brookfield Infrastructure Reports Strong Third Quarter 2025 Results
-
K-Tech Rings the Closing Bell on the Nasdaq
-
Mobilicom Secures Follow-On Production Order from Asia-Based Tier-1 Robotics Manufacturer Bringing Cumulative Orders to $315,000
-
GenVivo to Present Phase 1 Trial Results for GEN2, A Personalizing Systemic Cancer Immunotherapy, at the 2025 Society for Immunotherapy of Cancer (SITC) Annual Meeting
-
Inspired Announces Closing of Sale of UK Holiday Parks Business to Genda Inc.
-
HCW Biologics Presents Preclinical Data for TRBC-Based T-Cell Engager Program at the Society for Immunotherapy of Cancer’s (SITC) 40th Annual Meeting
-
Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025
-
Quantum Biopharma Reports Strong Third Quarter Results Maintaining ‘No Going Concern’ Status with Cash Runway Extending Beyond March 2027, and $572,000 USD Gains in Crypto Portfolio
-
AMC Networks Inc. Reports Third Quarter 2025 Results
-
RYTHM, Inc. Reports Third Quarter 2025 Results
-
Hain Celestial Reports Fiscal First Quarter 2026 Financial Results
